Aclaris Therapeutics, Inc.
Moat Score — Aclaris Therapeutics, Inc.
Total Moat Score
6 / 30
| Moat Factor | Score | Analysis |
|---|---|---|
| Intangible Assets Patents, trademarks, brand strength, or regulatory licenses that protect a company's products or services from being freely copied by competitors. | 3 / 5 | Aclaris's proprietary covalent kinase inhibitor chemistry platform and associated composition-of-matter patents on candidates like zunsemetinib provide a real, differentiated intellectual property base for designing selective anti-inflammatory drugs. |
| Cost Advantage A durable ability to produce goods or services more cheaply than competitors — through scale, unique access to cheap inputs, location, or process — that lets a company undercut rivals or out-earn them at the same price. | 0 / 5 | As a small clinical-stage biotech, Aclaris has no manufacturing or commercial scale advantage versus large immunology-focused pharmaceutical competitors. |
| Pricing Power The ability to raise prices without losing meaningful business, because the product or service is differentiated, mission-critical, or has few good substitutes. | 1 / 5 | With no approved products currently generating revenue, Aclaris has no realized pricing power; future pricing would depend on differentiation achieved versus established biologics and JAK inhibitors at the time of any approval. |
| Network Effect The product or service becomes more valuable to every user as more people or organizations use it, making an established leader harder to displace. | 0 / 5 | Small-molecule kinase inhibitor therapeutics do not exhibit network effects. |
| Switching Costs The money, time, or operational disruption a customer would face switching to a competitor, which locks in existing customers and supports renewals. | 1 / 5 | With no commercialized product currently on the market, there are no entrenched prescribers or patients creating switching costs for Aclaris's pipeline candidates today. |
| Efficient Scale A market that can only profitably support a small number of players, so incumbents face limited threat from new entrants even without other defenses. | 1 / 5 | The immuno-inflammatory disease market is large and supports numerous well-funded competitors including major pharmaceutical companies, so efficient scale provides little structural protection for a smaller platform company like Aclaris. |